Bruker & the Institute of Medical Microbiology at the University of Zurich Announce a Collaboration for Mass Spectrometry-bas...
June 27 2011 - 12:00AM
Business Wire
At the 4th Congress of European Microbiologists (Federation of
European Microbiological Societies, or FEMS) meeting in Geneva,
Bruker announces a collaboration with the Institute of Medical
Microbiology (IMM) at the University of Zurich (www.imm.uzh.ch).
The IMM is using Bruker´s MALDI Biotyper system as their
next-generation, rapid microbial identification system. The
Institute of Medical Microbiology is the Swiss national reference
centre for mycobacteria and its strain collections of coryneform
bacteria, actinomycetes and fastidious gram negative bacteria and
moulds are acknowledged worldwide. The IMM is faced with the
characterization and identification of challenging microorganisms
on a daily base. Therefore, the IMM has developed their own
algorithms and workflows for identification and antibiotics
susceptibility testing (AST). Their AST approaches are mainly based
on Kirby-Bauer testing methods, which are now applied in
combination with MALDI-TOF based identification technology.
The focus of the collaboration between the Institute of Medical
Microbiology and Bruker is the field of coryneform bacteria,
actinomycetes, fastidious gram negative bacteria and moulds. The
identification of these microorganisms is one of the most
challenging tasks of many microbiological laboratories. The
MALDI Biotyper provides a substantial contribution to a more
thorough characterization of this group of microorganisms.
Furthermore, the IMM microbiologists designed a study to validate
the analytical performance of the MALDI Biotyper against
their own molecular-characterized strain collection. Based on the
results, the MALDI Biotyper reference library will be
further extended. This will further improve its proven outstanding
identification performance.
Dr. Michael Hombach, the Associate Head of Bacteriology at the
Institute of Medical Microbiology, stated: “We have started the
collaboration with Bruker to further develop the MALDI-TOF based
microorganisms identification system, because the MALDI
Biotyper has the potential to improve and support our
microbiology identification strategy due to its quick and accurate
performance in identifying difficult bacteria, yeasts and fungi
samples. During our daily routine we increasingly face the problem
of a broadening spectrum of infections and of complex resistance
patterns. In order to keep up with fast modifications of microbial
species characteristics, the open and flexible concept of the
MALDI Biotyper is a promising solution to further improve
the performance of our diagnostic lab.”
Dr. Guido Mix, Director of Microbiology Sales at Bruker
Daltonics, commented further: “The collaboration with the Institute
of Medical Microbiology support our efforts to provide novel and
advanced tools to the microbiologists that make daily
identifications faster and easier. The comprehensive and worldwide
acknowledged expertise of the IMM in the field of coryneform
bacteria, actinomycetes, fastidious Gram-negative rods and moulds
will also be adopted in our developments. Thus, MALDI
Biotyper based confident identification even of these
challenging microorganisms will become more established in
microbiologists’ daily work.”
About the Bruker MALDI Biotyper
Bruker’s dedicated MALDI Biotyper solution enables
molecular identification, taxonomical classification or
dereplication of microorganisms like bacteria, yeasts and fungi.
Classification and identification of microorganisms is achieved
reliably and fast using proteomic fingerprinting with
high-throughput MALDI-TOF mass spectrometry. Applications include
clinical routine microbial identification, environmental and
pharmaceutical analysis, taxonomical research, food and consumer
product processing and quality control, as well as in marine
microbiology. Bruker’s robust MALDI Biotyper method requires
minimal sample preparation efforts and offers low cost per sample.
The MALDI Biotyper is available in a research-use-only
version, as well as in an IVD version according to the EU directive
EC/98/79 in certain EU countries. For more information, please
visit www.bdal.com/maldibiotyper.
For more information about Bruker Daltonics and Bruker
Corporation (NASDAQ: BRKR), please visit www.bdal.com and
www.bruker.com.
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Sep 2024 to Oct 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Oct 2023 to Oct 2024